Background: Liso-cel is an autologous, CD19-directed, CAR T cell product administered at equal target doses of CD8+ and CD4+ CAR+ T cells. Results of a prespecified interim analysis of the TRANSFORM study (NCT03575351) demonstrated superior efficacy of liso-cel compared with the SOC of salvage immunochemotherapy (CT) followed by high-dose chemotherapy and ASCT in responders, as 2L treatment for patients (pts) with LBCL primary refractory to or relapsed within 12 months of first-line (1L) therapy (Kamdar et al. Lancet 2022). At the interim analysis, the primary endpoint of EFS and key secondary endpoints of CR rate and PFS met statistical significance in favor of liso-cel and OS data were immature. Here we report results from the primary analysis with a median follow-up of 17.5 months.

Methods: TRANSFORM is a global, randomized, multicenter, phase 3 study comparing efficacy and safety of liso-cel versus SOC (R-DHAP, R-ICE, or R-GDP followed by BEAM + ASCT) in adults (aged ≤ 75 years) with LBCL primary refractory to or relapsed ≤ 12 months after 1L therapy who were eligible for ASCT. Key inclusion criteria were ECOG PS ≤ 1 and adequate organ function. Pts in the liso-cel arm underwent lymphodepletion with fludarabine/cyclophosphamide followed by liso-cel at a target dose of 100 × 106 CAR+ T cells. Bridging therapy with R-DHAP, R-ICE or R-GDP was allowed at investigator discretion. Pts in the SOC arm received 3 cycles of CT. Responding pts (CR or PR) proceeded to high-dose chemotherapy + ASCT. Crossover to receive liso-cel was allowed for pts in the SOC arm not achieving CR or PR after 3 cycles of CT, not in CR after ASCT, or demonstrating PD at any time.

The primary endpoint was event-free survival (EFS) based on independent review committee (IRC). Key secondary endpoints included IRC-assessed CR rate, PFS, and OS. The primary endpoint of EFS was met at the interim analysis and is updated here; thus, only the key secondary endpoints were retested at the primary analysis, as prespecified by the statistical analysis plan. The significance threshold to reject the null hypothesis for the key secondary endpoints was ≤ 0.021 (adjusted for the actual number of events available for analysis and the alpha spent at previous interim analyses). Median follow-up for the primary analysis was 17.5 months (range, 0.9‒37.0).

Results: A total of 184 pts were randomized, with 92 pts in each arm. Baseline characteristics were as previously reported, 33% of pts were aged ≥ 65 y, 64% had DLBCL (55% not otherwise specified, 8% transformed from indolent lymphomas), 12.5% had double-hit lymphoma, and 73% were refractory (PD, stable disease, PR, or CR with relapse within 3 months) to 1L therapy. Median (95% CI) EFS was not reached (NR; 9.5-NR) for liso-cel versus 2.4 months (2.2-4.9) for SOC (Figure). CR rate and PFS met statistical significance; CR rate was 74% for liso-cel versus 43% for SOC (P < 0.0001) and median PFS (95% CI) was NR (12.6-NR) for liso-cel versus 6.2 months (4.3-8.6) for SOC (HR, 0.400; P < 0.0001) (Table). Of 26 pts with a PR at the interim analysis, the response deepened to CR for 9 pts at the primary analysis (6/18 in the liso-cel arm; 3/8 in the SOC arm). Of 91 pts treated in the SOC arm, 61 (67%) crossed over to receive liso-cel. At the primary analysis, 66 pts had died (28 in the liso-cel arm and 38 in the SOC arm, including 29 after crossover); the most frequent cause of death was disease progression. Median OS favored liso-cel versus SOC, although it did not meet statistical significance (NR versus 29.9 mo, respectively; HR, 0.724; P = 0.0987). Safety results were consistent with those reported in the interim analysis.

Conclusions: This primary analysis, with a median follow-up of 17.5 months, confirmed the clinical benefit of liso-cel over SOC. In TRANSFORM, liso-cel resulted in statistically significant and clinically meaningful improvements in EFS, CR rate, and PFS. These data reinforce liso-cel as a 2L treatment in pts with primary refractory or early relapsed LBCL.

Figure 1
Figure 1
View largeDownload PPT

Abramson:Regeneron: Consultancy; MorphoSys: Consultancy; Mustang Bio: Consultancy; Ono Pharma: Consultancy; Genmab: Consultancy; Kite Pharma: Consultancy; Incyte: Consultancy; Bluebird bio: Consultancy; Kymera: Consultancy; BeiGene: Consultancy; Epizyme: Consultancy; Genentech: Consultancy; Abbvie: Consultancy; BMS: Consultancy, Research Funding; Century: Consultancy; Astra-Zeneca: Consultancy; Lilly: Consultancy; Janssen: Consultancy; Seattle Genetics: Research Funding. Arnason:Bristol Myers Squibb: Speakers Bureau. Glass:Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria; Gilead: Consultancy; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Bachanova:ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees; Citius Pharma: Research Funding; FATA Therapeutics: Research Funding; Incyte: Research Funding; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Karyopharma: Consultancy; Gamida Cell: Membership on an entity's Board of Directors or advisory committees, Research Funding. Ibrahimi:KARYOPHARM THERAPUTICS: Divested equity in a private or publicly-traded company in the past 24 months. Mielke:Celgene/BMS: Other: via my institution, Speakers Bureau; Novartis: Other: via my institution, Speakers Bureau; KITE/GILEAD: Other: Expert Panel with travel costs; via my institution; Miltenyi: Other: DSMB via my institution; Immunicum: Other: DSMB via my institution; DNA Prime SA: Other: via my institution, Speakers Bureau. Mutsaers:Glaxo Smith Kline: Consultancy; Astra Zeneca: Research Funding; BMS: Consultancy. Izutsu:Chugai: Consultancy, Honoraria, Research Funding; Eli Lilly and Company: Consultancy, Honoraria; Merck Sharp & Dohme: Honoraria, Research Funding; Eizai: Honoraria, Research Funding; Incyte: Research Funding; Yakult: Research Funding; Kyowa Kirin: Honoraria, Research Funding; Daiichi Sankyo: Honoraria, Research Funding; Genmab: Research Funding; Loxo Oncology: Research Funding; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Symbio: Honoraria; Takeda: Honoraria; Novartis: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria, Research Funding; Janssen: Research Funding; Ono Pharmaceutical: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding; Beigene: Consultancy, Research Funding. Morschhauser:Janssen: Speakers Bureau; Miltenyi: Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; Genmab: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Allogene therapeutics: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead Sciences: Consultancy, Membership on an entity's Board of Directors or advisory committees. Lunning:TG Therapeutics: Consultancy; Morphosys: Consultancy; Kite, a Gilead Company: Consultancy; Janssen: Consultancy; Diiachi-Sankyo: Consultancy; Astra-Zeneca: Consultancy; ADC Therapeutics: Consultancy; Acrotech: Consultancy; AbbVie: Consultancy; Astellas: Consultancy; BMS: Consultancy, Research Funding; EUSA: Consultancy; Fate Therapeutics: Consultancy; Genentech: Consultancy; Genmab: Consultancy; Nurix Therapeutics: Consultancy; Seattle Genetics: Consultancy; CURIS: Research Funding; Pharmacyclics: Consultancy. Crotta:BMS: Current Employment, Current equity holder in publicly-traded company. Montheard:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company; Novartis Pharma AG: Current equity holder in publicly-traded company; Alcon: Current equity holder in publicly-traded company. Previtali:Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company. Kamdar:Abbvie: Consultancy; Novartis: Research Funding; Genentech: Consultancy, Other: DMC, Research Funding; TG Therapeutics: Consultancy, Research Funding; AstraZeneca: Consultancy; BMS: Consultancy; Adaptive Technologies: Consultancy; ADC Therapeutics: Consultancy; Beigene: Consultancy; Impact Bio: Consultancy; SeaGen: Speakers Bureau; Celgene: Other: DMC.

Author notes

*

Asterisk with author names denotes non-ASH members.

© 2022 by The American Society of Hematology
2022
Sign in via your Institution